JP2017521486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017521486A5 JP2017521486A5 JP2017516251A JP2017516251A JP2017521486A5 JP 2017521486 A5 JP2017521486 A5 JP 2017521486A5 JP 2017516251 A JP2017516251 A JP 2017516251A JP 2017516251 A JP2017516251 A JP 2017516251A JP 2017521486 A5 JP2017521486 A5 JP 2017521486A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- peptide
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007159P | 2014-06-03 | 2014-06-03 | |
| US62/007,159 | 2014-06-03 | ||
| PCT/US2015/033509 WO2015187540A1 (en) | 2014-06-03 | 2015-06-01 | Peptide-drug conjugates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019107602A Division JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017521486A JP2017521486A (ja) | 2017-08-03 |
| JP2017521486A5 true JP2017521486A5 (enExample) | 2018-12-20 |
| JP6539729B2 JP6539729B2 (ja) | 2019-07-03 |
Family
ID=54700553
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516251A Active JP6539729B2 (ja) | 2014-06-03 | 2015-06-01 | ペプチド−薬物複合体 |
| JP2019107602A Pending JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019107602A Pending JP2019189623A (ja) | 2014-06-03 | 2019-06-10 | ペプチド−薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9579317B2 (enExample) |
| EP (1) | EP3152223B1 (enExample) |
| JP (2) | JP6539729B2 (enExample) |
| CN (1) | CN106456799B (enExample) |
| AU (1) | AU2015270924B2 (enExample) |
| CA (1) | CA2951049C (enExample) |
| ES (1) | ES2857192T3 (enExample) |
| MA (1) | MA40030A (enExample) |
| WO (1) | WO2015187540A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015306574B2 (en) * | 2014-08-22 | 2020-07-23 | Yafei Shanghai Biology Medicine Science & Technology Co. Ltd. | Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof |
| CN116059390A (zh) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
| CN107375288B (zh) | 2016-05-16 | 2019-08-23 | 博瑞生物医药（苏州）股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CN108314703B (zh) * | 2017-01-17 | 2022-02-01 | 亚飞（上海）生物医药科技有限公司 | 分子定点靶向和激活的激酶抑制剂的制备和用途 |
| KR102279429B1 (ko) | 2017-04-21 | 2021-07-20 | 브라이트제네 바이오-메디컬 테크놀로지 코., 엘티디. | 멀티 암 표적 항암 콘쥬게이트 |
| CN107670048B (zh) * | 2017-08-30 | 2019-04-26 | 南京明臻医药科技有限公司 | 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用 |
| WO2020146236A1 (en) * | 2019-01-07 | 2020-07-16 | Cenna Biosciences Inc. | Novel peptides and uses thereof |
| EP3946460A4 (en) * | 2019-04-05 | 2023-03-29 | Prolynx LLC | IMPROVED CONJUGATIONAL LINKERS |
| JP7475065B2 (ja) * | 2019-05-24 | 2024-04-26 | 真喜子 大城戸 | 薬剤、肺胞の洗浄用の薬液、及び、ネブライザー |
| EP4237011A4 (en) * | 2020-10-30 | 2026-01-07 | Avacta Life Sciences Ltd | EXTENDED SERUM HALF-LIFE ENZYME-ACTIVATED THERAPEUTIC CONJUGATES |
| KR20230141754A (ko) * | 2020-10-30 | 2023-10-10 | 아박타 라이프 사이언시스 리미티드 | Fap-활성화 혈청 반감기 연장된 치료 접합체 |
| CN115850288B (zh) * | 2022-11-25 | 2025-03-21 | 中科帅天医药(深圳)有限公司 | 一种丝裂霉素c前体药物及其制备方法和应用 |
| EP4676539A1 (en) * | 2023-03-09 | 2026-01-14 | BicycleTx Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| CN117683079B (zh) * | 2023-12-12 | 2025-04-04 | 九洲药业(杭州)有限公司 | 一种抗体偶联药物连接子的固相合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3803223A (en) * | 1970-07-20 | 1974-04-09 | Searle & Co | 3-amino-n-substituted succinamic acids and intermediates thereto |
| US6214345B1 (en) * | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| CN1406137A (zh) * | 2000-02-24 | 2003-03-26 | 杰南技术公司 | 天冬氨酸特异性半胱氨酸蛋白酶活化的前体药物治疗 |
| US8314060B2 (en) | 2000-09-05 | 2012-11-20 | Biosight Ltd. | Peptide conjugated anti-cancer prodrugs |
| EP1635858A4 (en) * | 2003-05-29 | 2009-08-26 | Scripps Research Inst | TARGETED DELIVERY TO LEGUMAIN EXPRESSING CELLS |
| CN101374856A (zh) | 2005-11-29 | 2009-02-25 | 斯克里普斯研究学院 | 抑制肿瘤细胞浸润、转移和血管生成 |
| EP2266964B1 (en) * | 2009-06-22 | 2013-01-09 | KTB Tumorforschungsgesellschaft mbH | Acid-labile trigger units |
| US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
| WO2012075472A2 (en) | 2010-12-03 | 2012-06-07 | Regents Of The University Of Colorado, A Body Corporate | Chemical entities and therapeutic uses thereof |
-
2015
- 2015-06-01 WO PCT/US2015/033509 patent/WO2015187540A1/en not_active Ceased
- 2015-06-01 EP EP15803150.0A patent/EP3152223B1/en active Active
- 2015-06-01 MA MA040030A patent/MA40030A/fr unknown
- 2015-06-01 ES ES15803150T patent/ES2857192T3/es active Active
- 2015-06-01 CA CA2951049A patent/CA2951049C/en active Active
- 2015-06-01 JP JP2017516251A patent/JP6539729B2/ja active Active
- 2015-06-01 AU AU2015270924A patent/AU2015270924B2/en active Active
- 2015-06-01 CN CN201580029854.5A patent/CN106456799B/zh active Active
- 2015-06-01 US US14/726,897 patent/US9579317B2/en active Active
-
2017
- 2017-01-27 US US15/417,615 patent/US20170232023A1/en not_active Abandoned
-
2019
- 2019-06-10 JP JP2019107602A patent/JP2019189623A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017521486A5 (enExample) | ||
| Araste et al. | Peptide-based targeted therapeutics: Focus on cancer treatment | |
| JP2019501204A5 (enExample) | ||
| JP2017171685A5 (enExample) | ||
| JP2021100937A5 (enExample) | ||
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| JP2011079858A5 (enExample) | ||
| JP2018502120A5 (enExample) | ||
| MX2019013701A (es) | Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos. | |
| EP2301531A3 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| JP2018503668A5 (enExample) | ||
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| JP2021505661A5 (enExample) | ||
| WO2005072061A3 (en) | Conjugates for cancer therapy and diagnosis | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| WO2016004048A3 (en) | Targeted conjugates and particles and formulations thereof | |
| JP2015502926A5 (enExample) | ||
| JP2017523184A5 (enExample) | ||
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| JP2017530184A5 (enExample) | ||
| FI3511004T3 (fi) | Yhdistelmävalmisteita syövän hoitoon | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| JP2016526021A5 (enExample) | ||
| RU2020102713A (ru) | Применение изовалерил-спирамицина i, ii и/или iii при изготовлении препарата для лечения и/или профилактики опухоли и получения лекарственного препарата | |
| JP2008514577A5 (enExample) |